DTIL
Price
$5.85
Change
-$0.15 (-2.50%)
Updated
Nov 13 closing price
Capitalization
77.42M
Intraday BUY SELL Signals
PMCB
Price
$0.79
Change
-$0.06 (-7.06%)
Updated
Nov 13 closing price
Capitalization
5.37M
33 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DTIL vs PMCB

Header iconDTIL vs PMCB Comparison
Open Charts DTIL vs PMCBBanner chart's image
Precision BioSciences
Price$5.85
Change-$0.15 (-2.50%)
Volume$168.74K
Capitalization77.42M
PharmaCyte Biotech
Price$0.79
Change-$0.06 (-7.06%)
Volume$57.45K
Capitalization5.37M
DTIL vs PMCB Comparison Chart in %
DTIL
Daily Signal:
Gain/Loss:
PMCB
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
DTIL vs. PMCB commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DTIL is a Hold and PMCB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (DTIL: $5.85 vs. PMCB: $0.79)
Brand notoriety: DTIL and PMCB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DTIL: 102% vs. PMCB: 72%
Market capitalization -- DTIL: $77.42M vs. PMCB: $5.37M
DTIL [@Biotechnology] is valued at $77.42M. PMCB’s [@Biotechnology] market capitalization is $5.37M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DTIL’s FA Score shows that 0 FA rating(s) are green whilePMCB’s FA Score has 1 green FA rating(s).

  • DTIL’s FA Score: 0 green, 5 red.
  • PMCB’s FA Score: 1 green, 4 red.
According to our system of comparison, both DTIL and PMCB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DTIL’s TA Score shows that 4 TA indicator(s) are bullish while PMCB’s TA Score has 4 bullish TA indicator(s).

  • DTIL’s TA Score: 4 bullish, 6 bearish.
  • PMCB’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both DTIL and PMCB are a bad buy in the short-term.

Price Growth

DTIL (@Biotechnology) experienced а -9.16% price change this week, while PMCB (@Biotechnology) price change was -6.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.47%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +62.00%.

Reported Earning Dates

PMCB is expected to report earnings on Dec 17, 2025.

Industries' Descriptions

@Biotechnology (+1.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DTIL($77.4M) has a higher market cap than PMCB($5.37M). PMCB has higher P/E ratio than DTIL: PMCB (13.17) vs DTIL (4.53). DTIL YTD gains are higher at: 53.543 vs. PMCB (-45.771). PMCB has higher annual earnings (EBITDA): -3.96M vs. DTIL (-73.73M). DTIL has more cash in the bank: 62.2M vs. PMCB (13.4M). PMCB has less debt than DTIL: PMCB (75.2K) vs DTIL (29.4M). DTIL has higher revenues than PMCB: DTIL (1.26M) vs PMCB (0).
DTILPMCBDTIL / PMCB
Capitalization77.4M5.37M1,442%
EBITDA-73.73M-3.96M1,863%
Gain YTD53.543-45.771-117%
P/E Ratio4.5313.1734%
Revenue1.26M0-
Total Cash62.2M13.4M464%
Total Debt29.4M75.2K39,096%
FUNDAMENTALS RATINGS
DTIL vs PMCB: Fundamental Ratings
DTIL
PMCB
OUTLOOK RATING
1..100
6956
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
58
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9994
PRICE GROWTH RATING
1..100
4664
P/E GROWTH RATING
1..100
1003
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DTIL's Valuation (54) in the Biotechnology industry is in the same range as PMCB (58) in the null industry. This means that DTIL’s stock grew similarly to PMCB’s over the last 12 months.

DTIL's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PMCB (100) in the null industry. This means that DTIL’s stock grew similarly to PMCB’s over the last 12 months.

PMCB's SMR Rating (94) in the null industry is in the same range as DTIL (99) in the Biotechnology industry. This means that PMCB’s stock grew similarly to DTIL’s over the last 12 months.

DTIL's Price Growth Rating (46) in the Biotechnology industry is in the same range as PMCB (64) in the null industry. This means that DTIL’s stock grew similarly to PMCB’s over the last 12 months.

PMCB's P/E Growth Rating (3) in the null industry is significantly better than the same rating for DTIL (100) in the Biotechnology industry. This means that PMCB’s stock grew significantly faster than DTIL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DTILPMCB
RSI
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 3 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 3 days ago
83%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 3 days ago
84%
MACD
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 3 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 18 days ago
77%
Bullish Trend 5 days ago
75%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 3 days ago
75%
Aroon
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 3 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
DTIL
Daily Signal:
Gain/Loss:
PMCB
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MYPS0.730.02
+2.99%
PLAYSTUDIOS
AMIX0.85N/A
-0.18%
Autonomix Medical Inc
NBIX146.85-0.44
-0.30%
Neurocrine Biosciences
DNA8.36-0.10
-1.18%
Ginkgo Bioworks Holdings
CIVI27.88-0.93
-3.23%
Civitas Resources

DTIL and

Correlation & Price change

A.I.dvisor indicates that over the last year, DTIL has been loosely correlated with AXON. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if DTIL jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DTIL
1D Price
Change %
DTIL100%
-2.50%
AXON - DTIL
46%
Loosely correlated
-2.15%
ORMP - DTIL
41%
Loosely correlated
-2.83%
ARRY - DTIL
39%
Loosely correlated
-9.63%
LEGN - DTIL
35%
Loosely correlated
-0.53%
IVEVF - DTIL
32%
Poorly correlated
N/A
More

PMCB and

Correlation & Price change

A.I.dvisor tells us that PMCB and FATE have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PMCB and FATE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PMCB
1D Price
Change %
PMCB100%
-3.03%
FATE - PMCB
33%
Poorly correlated
-7.14%
DAWN - PMCB
29%
Poorly correlated
-0.19%
MBRX - PMCB
28%
Poorly correlated
+1.82%
BTAI - PMCB
28%
Poorly correlated
-15.35%
DTIL - PMCB
28%
Poorly correlated
N/A
More